Early reduction of pulmonary arterial hypertension in patients using a long-term mechanical ventricular assistance device
a cross-sectional study
Keywords:
Pulmonary arterial hypertension, Heart failure, Heart-assist devicesAbstract
BACKGROUND: Severe pulmonary arterial hypertension (PAH) is a contraindication for heart transplantation (HT). It has been correlated with increased early and late mortality, mainly associated with right ventricular failure. Ventricular assistance devices (VADs) can promote reduction of intracardiac pressures and consequent reduction of PAH over the medium and long terms, thus enabling future candidature for HT. The diminution of early pulmonary pressure within this scenario remains unclear. OBJECTIVE: To evaluate the reduction of PAH and correlate data from right catheterization with the earliness of this reduction. DESIGN AND SETTING: Cross-sectional study in a general hospital in São Paulo, Brazil. METHODS: This was a retrospective analysis on the medical records of patients undergoing VAD implantation in a single hospital. Patients for whom VAD had been indicated as a bridge to candidature for HT due to their condition of constant PAH were selected. RESULTS: Four patients with VADs had constantly severe PAH. Their mean pulmonary artery systolic pressure (PASP) before VAD implantation was 66 mmHg. Over the 30-day period after the procedure, all the patients evolved with a drop in PASP to below 60 mmHg. Their new average was 36 mmHg, which was a drop of close to 50% from baseline values. The one-year survival of this sample was 100%. CONCLUSION: VAD implantation can reduce PAH levels. Early reduction occurred in all patients. Thus, use of VAD is an important bridge tool for enabling candidature for HT among patients with constantly severe PAH.
Downloads
References
Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96(4):1165-72. PMID: 9286945; https://doi.org/10.1161/01.cir.96.4.1165
Quader MA, Wolfe LG, Kasirajan V. Heart transplantation outcomes in patients with continuous-flow left ventricular assist device-related complications. J Heart Lung Transplant. 2015;34(1):75-81. PMID: 25150620; https://doi.org/10.1016/j.healun.2014.07.015
Gallagher RC, Kormos RL, Gasior T, et al. Univentricular support results in reduction of pulmonary resistance and improved right ventricular function. ASAIO Trans. 1991;37(3):M287-8. PMID: 1751153.
Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg. 2007;133(3):689-95. PMID: 17320566; https://doi.org/10.1016/j.jtcvs.2006.08.104
Miller LW, Guglin M. Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol. 2013;61(12):1209-21. PMID: 23290542; https://doi.org/10.1016/j.jacc.2012.08.1029
Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart Lung Transplant. 2010;29(2):201-8. PMID: 20113910; https://doi.org/10.1016/j.healun.2009.09.013
Salzberg SP, Lachat ML, von Harbou K, Zünd G, Turina MI. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg. 2005;27(2):222-5. PMID: 15691674; https://doi.org/10.1016/j.ejcts.2004.11.001
Haft J, Armstrong W, Dyke DB, et al. Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation. 2007;116(11 Suppl):I8-15. PMID: 17846330; https://doi.org/10.1161/CIRCULATIONHA.106.677898
Ozturk P, Engin AY, Nalbantgil S, et al. Comparison of continuous-flow and pulsatile-flow blood pumps on reducing pulmonary artery pressure in patients with fixed pulmonary hypertension. Artif Organs. 2013;37(9):763-7. PMID: 24033601; https://doi.org/10.1111/aor.12164
John R, Liao K, Kamdar F, et al. Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2010;140(2):447-52. PMID: 20435321; https://doi.org/10.1016/j.jtcvs.2010.03.006
Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495-504. PMID: 26520247; https://doi.org/10.1016/j.healun.2015.10.003
Cowger JA, Castle L, Aaronson KD, et al. The HeartMate II Risk Score: An Adjusted Score for Evaluation of All Continuous-Flow Left Ventricular Assist Devices. ASAIO J. 2016;62(3):281-5. PMID: 26955002; https://doi.org/10.1097/MAT.0000000000000362
